An issue of Endo International PLC (NASDAQ:ENDP) debt rose 2.3% as a percentage of its face value during trading on Wednesday. The debt issue has a 5.375% coupon and will mature on January 15, 2023. The bonds in the issue are now trading at $87.38 and were trading at $83.63 one week ago. Price moves in a company’s debt in credit markets often predict parallel moves in its stock price.
A number of equities analysts have recently weighed in on ENDP shares. Vetr upgraded Endo International PLC from a “hold” rating to a “buy” rating and set a $11.34 target price for the company in a report on Tuesday, May 9th. Mizuho reaffirmed a “buy” rating and issued a $18.00 price target (up previously from $17.00) on shares of Endo International PLC in a research report on Thursday, April 13th. Deutsche Bank AG reduced their price target on Endo International PLC from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, July 7th. BMO Capital Markets reissued a “hold” rating and set a $16.00 target price on shares of Endo International PLC in a research report on Wednesday, May 17th. Finally, Canaccord Genuity set a $14.00 target price on Endo International PLC and gave the stock a “hold” rating in a research report on Thursday, May 11th. Two equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $17.33.
Shares of Endo International PLC (ENDP) traded down 1.16% during midday trading on Friday, hitting $11.03. The stock had a trading volume of 4,015,862 shares. The firm’s market cap is $2.46 billion. The firm has a 50-day moving average price of $11.48 and a 200-day moving average price of $11.84. Endo International PLC has a 1-year low of $9.70 and a 1-year high of $24.93.
Endo International PLC (NASDAQ:ENDP) last issued its quarterly earnings data on Tuesday, May 9th. The company reported $1.23 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.10 by $0.13. The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. Endo International PLC had a negative net margin of 82.93% and a positive return on equity of 25.32%. The firm’s revenue was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.08 EPS. On average, equities analysts anticipate that Endo International PLC will post $3.54 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the company. Comerica Bank boosted its stake in Endo International PLC by 233.7% in the first quarter. Comerica Bank now owns 153,881 shares of the company’s stock worth $1,736,000 after buying an additional 107,761 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock worth $25,345,000 after buying an additional 633,904 shares during the last quarter. Point View Wealth Management Inc. boosted its stake in Endo International PLC by 12.3% in the first quarter. Point View Wealth Management Inc. now owns 11,431 shares of the company’s stock worth $128,000 after buying an additional 1,254 shares during the last quarter. Capital Fund Management S.A. bought a new stake in Endo International PLC during the first quarter worth approximately $260,000. Finally, Canada Pension Plan Investment Board boosted its position in shares of Endo International PLC by 220.4% in the first quarter. Canada Pension Plan Investment Board now owns 292,216 shares of the company’s stock worth $3,261,000 after buying an additional 201,022 shares in the last quarter. Institutional investors and hedge funds own 93.15% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Endo International PLC (NASDAQ:ENDP) Bond Prices Rise 2.3%” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://stocknewstimes.com/2017/07/29/endo-international-plc-nasdaqendp-bonds-trading-2-3-higher-updated.html.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.
